Edesa Biotech reports developments as a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases. Its recurring news centers on paridiprubart, or EB05, an anti-TLR4 antibody evaluated for Acute Respiratory Distress Syndrome, and EB06, an anti-CXCL10 monoclonal antibody program for moderate-to-severe nonsegmental vitiligo.
Company updates also cover clinical data presentations, manufacturing and regulatory preparation, government-supported research activities, conference participation, operating results, capital-structure matters and shareholder governance. Financial reports generally frame spending around clinical development priorities and the company’s monoclonal antibody pipeline.
Edesa Biotech (NASDAQ:EDSA) reported financial results for Q3 and nine months ended June 30, 2022. The company expanded its Phase 3 drug study for Covid-19 patients and confirmed robust recruitment for its Phase 2b dermatology study. Q3 operational expenses decreased to $5.80 million, while net loss was $5.79 million. For the nine months, total operating expenses dropped to $15.53 million, with a net loss of $14.74 million. Edesa holds $12.81 million in cash, with plans to participate in the H.C. Wainwright Global Investment Conference in September 2022.
Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, will partake in the BTIG Biotechnology Conference in New York on August 8-9, 2022. This hybrid event allows for both virtual and in-person attendance. Interested parties can connect with Edesa through BTIG representatives or via email at investors@edesabiotech.com. Edesa is advancing two critical product candidates, EB05, targeting Acute Respiratory Distress Syndrome, and EB01, for chronic allergic contact dermatitis.
Edesa Biotech, focusing on inflammatory and immune-related diseases, will present at the 2nd Annual ARDS Drug Development Summit on July 14, 2022, in Boston. CEO Par Nijhawan is set to discuss the EB05 drug candidate, a potential treatment for Acute Respiratory Distress Syndrome (ARDS), highlighting its Phase 2/3 clinical trial design influenced by Covid-19. Edesa's EB05 has shown a promising 68.5% reduction in mortality among critically ill Covid-19 patients. Additionally, the press release provides insights into the company's clinical programs for EB01 and their ongoing studies.
Edesa Biotech (Nasdaq: EDSA) has initiated enrollment for a second cohort in the Phase 3 study of its monoclonal antibody EB05, targeting Covid-19-induced Acute Respiratory Distress Syndrome (ARDS). This cohort includes hospitalized patients on invasive mechanical ventilation. The aim is to utilize EB05 earlier to reduce ICU stays and mortality. Recruitment is ongoing for approximately 500 subjects, with primary endpoints focusing on ventilator-free days and mortality rates at 28 and 60 days. Regulatory approval has been secured in Canada, Colombia, and Poland, with discussions ongoing in the U.S.
Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced that CEO Par Nijhawan, MD, will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. An on-demand presentation will be available from May 24 at 7:00 am ET on the Edesa website. Additionally, senior management will hold one-on-one meetings with attendees. Edesa is developing lead candidates EB05 and EB01 for ARDS and chronic allergic contact dermatitis, respectively.
Edesa Biotech (NASDAQ:EDSA) reported financial results for the first half of 2022, highlighting a net loss of $8.95 million, or $0.66 per share, an increase from a loss of $4.90 million in 2021. Operating expenses decreased to $9.74 million, attributed to lower R&D costs which fell to $6.99 million. The Phase 3 study for its Covid-19 treatment is underway, with over 25% of subjects randomized, and its dermatology study is 75% enrolled. The company raised approximately $11.6 million to strengthen its balance sheet, facilitating clinical advancements.
Edesa Biotech (NASDAQ:EDSA) announced that enrollment for its Phase 2b study of EB01, an anti-inflammatory drug for chronic allergic contact dermatitis, is progressing ahead of schedule. The company aims to complete enrollment of 210 subjects by Q4 2022, with topline data expected in Q1 2023. Positive interim data and strong interest in the drug’s novel mechanism are driving recruitment. EB01, a non-steroidal compound, targets inflammatory mechanisms potentially providing an effective alternative to steroids, addressing a significant unmet medical need among ACD patients.
Edesa Biotech, Inc. (NASDAQ:EDSA) has appointed Jennifer M. Chao to its Board of Directors, marking a significant move as the company approaches key milestones in its clinical programs. With over 25 years in biotech finance and corporate strategy, Chao is expected to provide valuable insights. She previously served in executive roles at major firms and is currently a board member at Endo International plc and Cardiol Therapeutics Inc. Edesa continues to focus on developing therapies for inflammatory and immune-related diseases, notably EB05 for Acute Respiratory Distress Syndrome and EB01 for allergic contact dermatitis.
Edesa Biotech (NASDAQ:EDSA) closed a registered direct offering of 2,739,727 common shares at $3.65 each, generating approximately $10 million in gross proceeds. The offering included warrants for the purchase of an equal number of shares at an exercise price of $3.52, valid for five and a half years. The funds will be used for working capital and corporate purposes. The company, focused on inflammatory and immune-related diseases, has two lead candidates in clinical trials: EB05 for Acute Respiratory Distress Syndrome and EB01 for chronic allergic contact dermatitis.
Edesa Biotech (NASDAQ:EDSA) announced a definitive agreement for a registered direct offering of 2,739,727 common shares at $3.65 each, estimated to raise $10 million before fees. The offering is expected to close around March 24, 2022. Concurrently, the company will issue warrants for an equal number of shares at an exercise price of $3.52, valid for five and a half years. Proceeds will be allocated for working capital and general corporate purposes, furthering Edesa's focus on innovative treatments for inflammatory diseases.